Ultraspound-guided Intralesional Injection of Cystic Hygr... | NCT07246928

Studies
Ultraspound-guided Intralesional Injection of Cystic Hygroma - A Case Report

NCT07246928

Sponsor

Delta University for Science and Technology

Status

Completed

Last Update Posted

Apr 30, 2026Actual

Enrollment

1Actual

Phase

Not Applicable

Conditions

Intralesional Injection of Cystic Hygroma
Cystic Hygroma (Macro-cystic Lymphatic Malformation)

Interventions

Intralesional Injection of Bleomycin

Countries

Egypt

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Oct 2025

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Sep 1, 2024Actual

Primary Completion Date

Sep 1, 2025Actual

Completion Date

Oct 6, 2025Actual

First Submitted Date

Nov 19, 2025

First Submission Date that Met QC Criteria

Nov 19, 2025

First Posted Date

Nov 24, 2025Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Apr 26, 2026

Last Update Posted Date

Apr 30, 2026Actual

Sponsor/Collaborators Module

Responsible Party, by Official Title

Sarah Arafat, Lecturer of Oral and Maxillofacial Surgery, Faculty of Oral and Dental Medicine, Delta University for Science & Technology, Delta University for Science and TechnologyPrincipal Investigator

Lead Sponsor

Delta University for Science and TechnologyOTHER

Collaborators

Not provided

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Ultrasound-guided Intralesional Injection of Cystic Hygroma - A Case Report

Detailed Description

Ultrasound-guided Intralesional Injection of Cystic Hygroma [lymphatic malformation]

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

1Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
pediatric patient	Experimental		Procedure: Intralesional Injection of Bleomycin

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Intralesional Injection of Bleomycin	Procedure	Aspiration of Cystic Hygroma Fluid and Intralesional Injection	pediatric patient

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
improvement: change in lesion size	reduction in lesion size	one year
improvement: reduction of lesion size		one year

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Pediatric patients of age up to 12 years having cystic hygromas (macrocystic lymphatic malformations), from the vascular anomalies clinic at the pediatric surgery department in Cairo University Specialized Pediatric Hospital (Abu EL-Reesh hospital). -

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

1 Month

Maximum Age

12 Years

Standard Ages

Child

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Gamal El-Tagy, MD	pediatric surgery department, Cairo University	Study Director

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Specialized Pediatric Hospital (Abu EL-Reesh Japanese hospital)		Cairo	Cairo Governorate	12613	Egypt

References Module

Citations

Not provided

ID	Term
D008202	Lymphangioma
D018190	Neoplasm, Lymphatic Tissue
D009370	Neoplasms by Histologic Type
D009369	Neoplasms